Avian Influenza in Humans: Zoonotic Transmission, Clinical Presentation, and One Health Surveillance

Introduction

Avian influenza viruses are type A orthomyxoviruses that primarily circulate among wild waterfowl and shorebirds. These viruses possess a segmented RNA genome encoding hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins. While most avian influenza virus subtypes are nonpathogenic in their natural reservoir hosts, certain strains have acquired the capacity for direct zoonotic transmission to humans. This article examines the virological, clinical, and epidemiological dimensions of avian influenza virus spillover to humans within the context of One Health surveillance frameworks. The emphasis is on the biological mechanisms that enable interspecies transmission and the resulting clinical manifestations observed in human cases. Readers should refer to the companion article Highly Pathogenic Avian Influenza (H5N1) in Poultry and Wild Birds: Clinical Signs, Transmission Dynamics, and Surveillance Maps for detailed coverage of avian clinical disease.

Virological Basis for Zoonotic Transmission

Receptor Binding Specificity

The barrier to direct avian-to-human transmission is primarily governed by the binding affinity of the viral HA protein for sialic acid (Sia) receptors on host epithelial cells. Avian influenza viruses preferentially bind to Sia linked to galactose by an alpha-2,3 linkage (Sia-alpha-2,3-Gal). Human influenza viruses preferentially bind to Sia-alpha-2,6-Gal receptors. The human upper respiratory tract expresses predominantly Sia-alpha-2,6-Gal, whereas the lower respiratory tract and the conjunctival epithelium express both receptor types. Subtypes such as H5N1 and H7N9 retain avian-type receptor specificity yet can infect humans through deep lung deposition or direct ocular inoculation. Mutations in the HA receptor binding site (e.g., Q226L, G228S in H2 and H3 numbering) can shift binding preference toward human-type receptors, a critical step in pandemic emergence.

Viral Polymerase Adaptation

The avian influenza virus RNA-dependent RNA polymerase, composed of PB2, PB1, and PA subunits, functions optimally at 41 degrees Celsius in avian intestinal cells. Replication in the human upper respiratory tract (32 to 34 degrees Celsius) requires adaptive mutations. The PB2 E627K substitution is a hallmark of mammalian adaptation and permits efficient replication at lower temperatures. This mutation has been identified in human isolates of H5N1, H7N9, and H9N2 subtypes. Additional PB2 mutations such as D701N and K526R further enhance replication competence in mammalian cells.

Subtypes with Documented Zoonotic Capacity

Several avian influenza virus subtypes have caused confirmed human infections:

Routes of Transmission from Birds to Humans

Direct Contact with Infected Poultry

The overwhelming majority of human infections result from direct or indirect contact with infected domestic poultry, particularly chickens, ducks, and turkeys. Transmission occurs through handling of sick or dead birds, exposure to respiratory secretions and feces, and environmental contamination in live poultry markets. The virus is shed in high concentrations in avian respiratory and fecal material. Slaughtering, defeathering, and preparation of infected birds for consumption represent high-risk activities. Consumption of properly cooked poultry products has not been associated with transmission.

Environmental Exposure

Contaminated environments including poultry cages, feed, water sources, and soil can serve as fomites. The virus remains infectious for extended periods in aquatic environments at low temperatures. Airborne transmission over short distances within enclosed poultry facilities is possible. The Avian Cholera in Waterfowl: Pasteurella multocida Serotypes, Outbreak Dynamics, and Vaccination Approaches in Wild and Domestic Birds article discusses analogous environmental persistence mechanisms for bacterial pathogens in similar ecological niches.

Wild Bird Interface

Wild waterfowl and shorebirds serve as the natural reservoir for all avian influenza virus subtypes. Human infections from direct contact with wild birds are rare but documented. The interface between wild birds, domestic poultry, and humans is a critical transmission nexus. The article Tularemia in Wildlife: Francisella tularensis Epidemiology, Diagnostics, and One Health Surveillance provides a comparable one health model for wildlife-origin zoonotic pathogens.

Limited Human-to-Human Transmission

Sustained human-to-human transmission has not been documented for any avian influenza virus subtype. However, limited, nonsustained transmission has occurred among close household contacts and healthcare workers during H5N1 and H7N9 outbreaks. This typically requires prolonged, unprotected exposure to severely ill index cases. Each human infection provides an opportunity for viral adaptation, underscoring the importance of rapid case identification and isolation.

Clinical Presentation in Humans

The clinical spectrum of avian influenza in humans ranges from mild upper respiratory tract infection to fulminant viral pneumonia with multiorgan failure. The case fatality rate varies by subtype and access to medical care. Historical data indicate case fatality rates of approximately 60 percent for H5N1 and 40 percent for H7N9, although these figures are influenced by reporting bias toward severe cases.

Incubation Period

The incubation period for avian influenza virus infection in humans ranges from 2 to 8 days, with a median of approximately 5 days. Longer incubation periods have been reported for H5N1 compared to seasonal influenza.

Clinical Signs and Symptoms

Fever is the most consistent presenting sign, typically exceeding 38 degrees Celsius. Cough is present in over 90 percent of cases and is initially dry, progressing to productive with mucoid or hemorrhagic sputum. Dyspnea develops within days of symptom onset and may progress rapidly to acute respiratory distress syndrome (ARDS). Conjunctivitis is a distinguishing feature of H7N7 and some H7N9 infections, reflecting the expression of avian-type receptors on ocular epithelium. Other common symptoms include sore throat, rhinorrhea, myalgia, headache, and malaise. Gastrointestinal symptoms including diarrhea, vomiting, and abdominal pain are more frequently reported with H5N1 infection compared to H7N9.

Severe Disease Progression

Approximately 60 to 80 percent of hospitalized cases develop viral pneumonia requiring supplemental oxygen. Progression to ARDS occurs within 5 to 7 days of symptom onset. Extrapulmonary manifestations include lymphopenia, elevated hepatic transaminases, acute kidney injury, and disseminated intravascular coagulation. Viral myocarditis and encephalitis have been reported in a minority of cases. Secondary bacterial pneumonia with pathogens such as Staphylococcus aureus and Streptococcus pneumoniae adds to disease severity, analogous to complications described in Poultry Bacteria Infections: Comprehensive Overview of Pathogenesis, Diagnosis, and Antimicrobial Strategies.

Laboratory and Radiographic Findings

Leukopenia, particularly lymphopenia, is a hallmark laboratory finding. Thrombocytopenia and elevated C-reactive protein are common. Chest radiography shows bilateral diffuse infiltrates, consolidation, and patchy opacities consistent with viral pneumonitis. Multilobar involvement is common, and pleural effusion may be present in severe cases.

Diagnostic Approaches

Molecular Detection

Real-time reverse transcription polymerase chain reaction (RT-PCR) targeting the matrix gene (M gene) is the primary diagnostic method. Subtype-specific assays targeting H5, H7, and H9 HA genes allow simultaneous detection and subtyping. Specimens should be collected from the upper respiratory tract (nasopharyngeal swab, throat swab) and lower respiratory tract (bronchoalveolar lavage, tracheal aspirate) in hospitalized patients. Lower respiratory tract specimens yield higher viral loads and greater diagnostic sensitivity. Viral RNA detection in blood is associated with severe disease and poor prognosis.

Virus Isolation

Isolation in embryonated chicken eggs or MDCK cells remains the gold standard for confirmatory diagnosis and antigenic characterization. This requires biosafety level 3 laboratory containment for highly pathogenic strains. The article Routes of Inoculation in Embryonated Eggs: A Technical Reference for Veterinary Virology describes the technical protocols relevant to avian influenza virus isolation.

Serology

Paired acute and convalescent sera are tested by hemagglutination inhibition or microneutralization assays. A fourfold or greater rise in antibody titer is considered diagnostic. Serologic surveys are essential for detecting mild or asymptomatic infections that are missed by clinical surveillance.

One Health Surveillance Framework

Animal Health Surveillance

Veterinary surveillance forms the foundation of early warning systems for zoonotic influenza. Active surveillance in domestic poultry focuses on detection of H5 and H7 subtypes in live bird markets, backyard flocks, and commercial farms. Wild bird surveillance targets migratory waterfowl at key stopover sites. The Highly Pathogenic Avian Influenza (HPAI) H5N1 in Poultry: Clinical Signs and Molecular Surveillance article provides detailed protocols for avian-side surveillance.

Human Health Surveillance

Case finding relies on syndromic surveillance for severe acute respiratory illness and influenza-like illness in populations with poultry exposure. Any person with fever and respiratory symptoms who has had contact with sick or dead poultry within 10 days should be tested. Enhanced surveillance during outbreaks includes contact tracing, healthcare worker monitoring, and community-based fever surveys.

Integrated Data Sharing

The World Organisation for Animal Health (WOAH) and the World Health Organization (WHO) coordinate global influenza surveillance through the Global Influenza Surveillance and Response System (GISRS). Shared databases track genetic and antigenic changes in circulating viruses. The WOAH standards for poultry health reporting are discussed in Poultry WOAH: Understanding World Organisation for Animal Health Standards for Avian Health.

One Health Surveillance Workflow

The following decision tree illustrates a One Health surveillance algorithm for avian influenza virus detection and response in human populations.

flowchart TD
    A[Poultry morbidity or mortality event], > B{Avian influenza virus testing}
    B, >|HPAI detected| C[Quarantine and culling]
    B, >|Low pathogenic detected| D[Routine surveillance]
    C, > E[Human contact tracing]
    D, > E
    E, > F{Symptomatic human contacts}
    F, >|Yes| G[Rapid respiratory specimen collection]
    F, >|No| H[Serologic survey for mild cases]
    G, > I[RT-PCR for influenza A and subtyping]
    I, > J{Positive for avian subtype}
    J, >|Yes| K[Isolation and antiviral treatment]
    J, >|No| L[Routine influenza case management]
    K, > M[Full genome sequencing]
    M, > N[Antigenic and genetic risk assessment]
    N, > O{Pandemic risk markers present}
    O, >|Yes| P[Global alert and vaccine seed strain preparation]
    O, >|No| Q[Enhanced local surveillance]

Biosecurity and Prevention

Poultry Sector Interventions

Live bird market closure and periodic rest days reduce virus circulation at the human-animal interface. Enhanced biosecurity measures include segregation of different poultry species, cleaning and disinfection protocols, and prevention of contact between domestic poultry and wild birds. Vaccination of poultry against H5 and H7 subtypes reduces viral shedding and transmission. The article Necrotic Enteritis in Broiler Chickens: Clostridium perfringens Virulence Factors, Gut Microbiome, and Probiotic Control Strategies discusses analogous biosecurity principles for bacterial disease control.

Personal Protective Measures

Poultry workers and those involved in culling operations should use N95 respirators, goggles, gloves, and protective clothing. Hand hygiene and respiratory etiquette reduce self-inoculation. Antiviral prophylaxis with neuraminidase inhibitors is recommended for high-risk exposures within 48 hours.

Conclusion

Avian influenza virus zoonosis represents a persistent pandemic threat requiring coordinated veterinary and human health surveillance. The clinical severity of H5N1 and H7N9 infections underscores the need for rapid diagnostic capacity and robust response systems at the animal-human interface. A One Health framework integrating molecular virology, clinical medicine, and ecological surveillance is essential for early detection and containment of emerging influenza strains with pandemic potential.

References

1. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiological Reviews. 1992;56(1):152-179.
2. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. New England Journal of Medicine. 2005;353(13):1374-1385.
3. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. New England Journal of Medicine. 2013;368(20):1888-1897.
4. World Health Organization. Avian influenza in humans: clinical management and infection control. WHO Guidelines.
5. World Organisation for Animal Health. Avian influenza: infection with avian influenza viruses. OIE Terrestrial Animal Health Code.
6. Peiris JSM, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clinical Microbiology Reviews. 2007;20(2):243-267.
7. Belser JA, Gustin KM, Pearce MB, Maines TR, Zeng H, Pappas C, et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature. 2013;501(7468):556-559.
8. Conenello GM, Tisoncik JR, Rosenzweig E, Varga ZT, Palese P, Katze MG. A single N66S mutation in the PB1-F2 protein of influenza A virus increases virulence by inhibiting the early interferon response in vivo. Journal of Virology. 2011;85(2):962-969.
9. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clinical Infectious Diseases. 2009;49(2):279-290.
10. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. Influenza virus receptors in the human airway. Nature. 2006;440(7083):435-436.